Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RLAY 
Relay Therapeutics Inc (RLAY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: RLAY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $13.1
1 Year Target Price $13.1
| 6 | Strong Buy |
| 5 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.71% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 636.20M USD | Price to earnings Ratio - | 1Y Target Price 13.1 |
Price to earnings Ratio - | 1Y Target Price 13.1 | ||
Volume (30-day avg) 13 | Beta 1.63 | 52 Weeks Range 1.77 - 10.72 | Updated Date 08/29/2025 |
52 Weeks Range 1.77 - 10.72 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.91 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.49 | Actual -0.41 |
Profitability
Profit Margin - | Operating Margin (TTM) -11011.37% |
Management Effectiveness
Return on Assets (TTM) -28.37% | Return on Equity (TTM) -46.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -7083267 | Price to Sales(TTM) 76.15 |
Enterprise Value -7083267 | Price to Sales(TTM) 76.15 | ||
Enterprise Value to Revenue 18.17 | Enterprise Value to EBITDA -0.8 | Shares Outstanding 172411008 | Shares Floating 102624444 |
Shares Outstanding 172411008 | Shares Floating 102624444 | ||
Percent Insiders 1.42 | Percent Institutions 100.48 |
Upturn AI SWOT
Relay Therapeutics Inc
Company Overview
History and Background
Relay Therapeutics, Inc. was founded in 2016. It focuses on discovering and developing protein motion-optimized medicines. The company aims to address unmet medical needs by targeting disease drivers with dynamic protein structures.
Core Business Areas
- Drug Discovery and Development: Relay Therapeutics focuses on discovering and developing novel therapies based on protein motion. Their platform integrates computational, biophysical, and chemical approaches to identify and develop drugs that modulate protein function.
Leadership and Structure
The leadership team includes Sanjiv Patel (President and CEO). The company has a board of directors and an R&D-focused organizational structure.
Top Products and Market Share
Key Offerings
- RLY-4008 (GAVRETO): A selective RET inhibitor being developed for RET-altered cancers. Gavreto (pralsetinib) developed by Blueprint Medicines, a Relay collaborator, also targets RET alterations. Relay's RLY-4008 is designed with improved selectivity. Competing RET inhibitors include selpercatinib (LOXO-292/Retevmo by Eli Lilly). Market share data is not currently available as Relay's RLY-4008 is still in clinical trials.
- RLY-2608: A PI3Ku03b1 inhibitor designed to target specific PI3Ku03b1 mutations in cancers, aiming for improved efficacy and reduced toxicity compared to existing PI3K inhibitors. Potential competitors include alpelisib (Piqray by Novartis). Market share data is not currently available as Relay's RLY-2608 is still in clinical trials.
Market Dynamics
Industry Overview
The oncology drug discovery and development market is highly competitive and rapidly evolving. It includes small molecule inhibitors, biologics, and cell therapies. Precision medicine is a growing trend, focusing on targeted therapies based on genetic and molecular profiles.
Positioning
Relay Therapeutics is positioned as a precision medicine company specializing in protein motion-optimized drug discovery. Its competitive advantage lies in its unique platform for identifying and developing drugs that modulate protein function.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is estimated to be in the hundreds of billions of dollars. Relay is positioning themselves to capture a piece of this by targeting specific mutations with potentially safer, more effective products
Upturn SWOT Analysis
Strengths
- Proprietary protein motion-optimized drug discovery platform
- Strong focus on precision medicine and targeted therapies
- Experienced leadership team
- Strategic collaborations with established pharmaceutical companies
- Promising pipeline of drug candidates
Weaknesses
- High R&D costs and long development timelines
- Dependence on successful clinical trial outcomes
- Competition from established pharmaceutical companies
- Reliance on funding for continued operations
- No products currently on the market
Opportunities
- Expanding pipeline to address additional cancer targets
- Partnering with other companies for drug development and commercialization
- Applying its platform to other disease areas
- Advancements in computational biology and drug discovery technologies
- Increasing demand for precision medicine approaches
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing and emerging therapies
- Patent challenges
- Economic downturns impacting R&D funding
Competitors and Market Share
Key Competitors
- LLY
- NVS
- BLU
Competitive Landscape
Relay Therapeutics' unique platform provides a competitive advantage, but it faces competition from larger pharmaceutical companies with more resources.
Growth Trajectory and Initiatives
Historical Growth: Relay Therapeutics has experienced growth in its pipeline and partnerships since its founding.
Future Projections: Analysts predict continued growth in R&D and potential revenue from future drug approvals, but no specific long term projections are publicly available for revenue.
Recent Initiatives: Recent initiatives include advancing clinical trials for RLY-4008 and RLY-2608.
Summary
Relay Therapeutics is a clinical-stage company with a promising drug discovery platform and pipeline. It is addressing large markets with specific drugs that target mutations. It has sufficient cash to operate in the short term. Success hinges on clinical trial results and potential partnership deals. They need to watch their burn-rate, as they are running at a significant loss.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Relay Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Relay Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2020-07-16 | CEO, President & Director Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS | ||
Sector Healthcare | Industry Biotechnology | Full time employees 197 | Website https://www.relaytx.com |
Full time employees 197 | Website https://www.relaytx.com | ||
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins; and RLY-1013, a degrader of estrogen receptor alpha. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.